Azilsartan

• CAT Number: A000335
• CAS Number: 147403-03-0
• Molecular Formula: C25H20N4O5
• Molecular Weight: 456.45
• Purity: ≥95%
• Synonyms: 147403-03-0; TAK-536; TAK 536; UNII-F9NUX55P23; CHEMBL57242
• Target: NF-κB
• Solubility: >17mg/mL in DMSO
• IUPAC Name: 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
• InChI: InChI=1S/C25H20N4O5/c1-2-33-24-26-20-9-5-8-19(23(30)31)21(20)29(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-27-25(32)34-28-22/h3-13H,2,14H2,1H3,(H,30,31)(H,27,28,32)
• InChIKey: KGSXMPPBFPAXLY-UHFFFAOYSA-N
• SMILES: CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O

Azilsartan（Cat No.:A000335）is an angiotensin II receptor blocker (ARB) used to treat hypertension. By selectively blocking the AT1 receptor, it prevents the action of angiotensin II, a hormone that causes blood vessels to constrict and raises blood pressure. Azilsartan helps relax blood vessels, lowering blood pressure and reducing the risk of cardiovascular events such as heart attack and stroke. It is known for its potency and long-lasting effects, providing sustained blood pressure control. Azilsartan is well-tolerated, with fewer side effects compared to other antihypertensive agents, making it a valuable option in hypertension management.

Reference

1: Hussain SA, Utba RM, Assumaidaee AM. Effects of Azilsartan, Aliskiren or their
Combination on High Fat Diet-induced Non-alcoholic Liver Disease Model in Rats.
Med Arch. 2017 Aug;71(4):251-255. doi: 10.5455/medarh.2017.71.251-255. PubMed
PMID: 28974844; PubMed Central PMCID: PMC5585811.

2: Fujiwara N, Tanaka A, Kawaguchi A, Tago M, Oyama JI, Uchida Y, Matsunaga K,
Moroe K, Toyoda S, Inoue T, Ikeda H, Node K; APEQ Study Investigators.
Association Between Blood Pressure Lowering and Quality of Life by Treatment of
Azilsartan. Int Heart J. 2017 Oct 21;58(5):752-761. doi: 10.1536/ihj.16-511. Epub
2017 Sep 30. PubMed PMID: 28966324.

3: Sukumaran V, Tsuchimochi H, Tatsumi E, Shirai M, Pearson JT. Azilsartan
ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of
ACE-2/ANG 1-7/Mas receptor cascade. Biochem Pharmacol. 2017 Nov 15;144:90-99.
doi: 10.1016/j.bcp.2017.07.022. Epub 2017 Aug 5. PubMed PMID: 28789938.

4: Dudkowski C, Karim A, Zhao Z, Alonso AB, Garg D, Preston RA. Single-Center
Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor
Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment. J Clin
Pharmacol. 2017 Jul 27. doi: 10.1002/jcph.970. [Epub ahead of print] PubMed PMID:
28750149.

5: Neutel JM, Cushman WC, Lloyd E, Barger B, Handley A. Comparison of long-term
safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs
olmesartan medoxomil/hydrochlorothiazide. J Clin Hypertens (Greenwich). 2017
Sep;19(9):874-883. doi: 10.1111/jch.13009. Epub 2017 Jul 6. PubMed PMID:
28681550.

6: Miyoshi T, Suetsuna R, Tokunaga N, Kusaka M, Tsuzaki R, Koten K, Kunihisa K,
Ito H. Effect of Azilsartan on Day-to-Day Variability in Home Blood Pressure: A
Prospective Multicenter Clinical Trial. J Clin Med Res. 2017 Jul;9(7):618-623.
doi: 10.14740/jocmr3050w. Epub 2017 May 22. PubMed PMID: 28611863; PubMed Central
PMCID: PMC5458660.

7: Shiga Y, Miura SI, Motozato K, Norimatsu K, Yano M, Hitaka Y, Adachi S, Kuwano
T, Inoue K, Inoue A, Fujisawa K, Shirotani T, Kusumoto T, Ideishi M, Saku K.
Comparison of Efficacy and Safety of Azilsartan and Olmesartan in Patients With
Essential Hypertension. Int Heart J. 2017 May 31;58(3):416-421. doi:
10.1536/ihj.16-285. Epub 2017 May 12. PubMed PMID: 28496022.

8: Johnson W, White WB, Sica D, Bakris GL, Weber MA, Handley A, Perez A, Cao C,
Kupfer S, Saunders EB. Evaluation of the angiotensin II receptor blocker
azilsartan medoxomil in African-American patients with hypertension. J Clin
Hypertens (Greenwich). 2017 Jul;19(7):695-701. doi: 10.1111/jch.12993. Epub 2017
May 11. PubMed PMID: 28493376.

9: Gao Q, Ou Z, Jiang T, Tian YY, Zhou JS, Wu L, Shi JQ, Zhang YD. Azilsartan
ameliorates apoptosis of dopaminergic neurons and rescues characteristic
parkinsonian behaviors in a rat model of Parkinson/’s disease. Oncotarget. 2017
Apr 11;8(15):24099-24109. doi: 10.18632/oncotarget.15732. PubMed PMID: 28445961;
PubMed Central PMCID: PMC5421830.

10: Hjermitslev M, Grimm DG, Wehland M, Simonsen U, Krüger M. Azilsartan
Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of
Hypertension. Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):225-233. doi:
10.1111/bcpt.12800. Epub 2017 Jun 19. Review. PubMed PMID: 28444983.